Academy Urges Insurers to Suspend Step Therapy Due to Potential Avastin Supply Issues
The Academy urged large commercial insurers and Medicare Advantage plans to suspend anti-VEGF step therapy requirements in response to Pine Pharmaceuticals discontinuation of repackaged Avastin (bevacizumab).
Member exclusive - Locked
May 18, 2022
Academy Shares Your Step Therapy Stories With CMS to Urge Policy Reversal
The Academy met with the Center for Medicare & Medicaid Services and other physician and patient groups to ask the agency to reinstate a step therapy prohibition for Medicare Advantage plans for Part B drugs.
